Efficacy and safety of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer: A systematic review and meta-analysis.

ABSTRACT:

Background

Trastuzumab deruxtecan (T-DXd) is a novel antibody-drug conjugate uesd for the treatment of HER2- positive (HER2+)breast cancer. This systematic review aimed to evaluate the efficacy and safety of T-DXd in advanced HER2-positive breast cancer.

Methods

PubMed, Web of Science and Embase databases were searched for literature on trastuzumab deruxtecan treatment for HER2-positive or low-expression breast cancer before December 30, 2024. The outcome measures were progression-free survival (PFS), overall survival (OS), objective response rates, and adverse events of any grade and grade ≥ 3. Meta-analysis of the relevant data was performed using Stata 14.0.

Results

A total of 2995 patients from 7 studies were included. The median PFS and median overall survival of

SUBMITTER: Mu Y 

PROVIDER: S-EPMC12622611 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature